Matt Larew
Stock Analyst at William Blair
(0.42)
# 4,178
Out of 5,058 analysts
14
Total ratings
33.33%
Success rate
-22.52%
Average return
Main Sectors:
Stocks Rated by Matt Larew
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRL Charles River Laboratories International | Upgrades: Outperform | n/a | $161.31 | - | 1 | Oct 6, 2025 | |
| TMO Thermo Fisher Scientific | Initiates: Outperform | n/a | $573.62 | - | 1 | Aug 19, 2025 | |
| MXCT MaxCyte | Downgrades: Market Perform | n/a | $1.65 | - | 2 | Aug 7, 2025 | |
| MRVI Maravai LifeSciences Holdings | Downgrades: Market Perform | n/a | $3.48 | - | 1 | Nov 8, 2024 | |
| DNA Ginkgo Bioworks Holdings | Downgrades: Underperform | n/a | $7.87 | - | 3 | May 10, 2024 | |
| ATR AptarGroup | Upgrades: Outperform | n/a | $119.48 | - | 1 | Apr 29, 2024 | |
| TECH Bio-Techne | Initiates: Outperform | n/a | $58.71 | - | 1 | Aug 28, 2023 | |
| AVTR Avantor | Downgrades: Market Perform | n/a | $10.98 | - | 1 | Jul 31, 2023 | |
| INNV InnovAge Holding | Downgrades: Market Perform | n/a | $5.03 | - | 2 | Sep 22, 2021 | |
| TWST Twist Bioscience | Initiates: Outperform | n/a | $26.27 | - | 1 | Jun 29, 2021 |
Charles River Laboratories International
Oct 6, 2025
Upgrades: Outperform
Price Target: n/a
Current: $161.31
Upside: -
Thermo Fisher Scientific
Aug 19, 2025
Initiates: Outperform
Price Target: n/a
Current: $573.62
Upside: -
MaxCyte
Aug 7, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $1.65
Upside: -
Maravai LifeSciences Holdings
Nov 8, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $3.48
Upside: -
Ginkgo Bioworks Holdings
May 10, 2024
Downgrades: Underperform
Price Target: n/a
Current: $7.87
Upside: -
AptarGroup
Apr 29, 2024
Upgrades: Outperform
Price Target: n/a
Current: $119.48
Upside: -
Bio-Techne
Aug 28, 2023
Initiates: Outperform
Price Target: n/a
Current: $58.71
Upside: -
Avantor
Jul 31, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $10.98
Upside: -
InnovAge Holding
Sep 22, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $5.03
Upside: -
Twist Bioscience
Jun 29, 2021
Initiates: Outperform
Price Target: n/a
Current: $26.27
Upside: -